Medical Cannabis Patient Therapies & Wellness Summit bring hospitals, health systems and provider groups together to discuss best practices, latest trends, and new innovative medical cannabis-based therapies and treatments to help patients diagnosed with serious diseases and behavioral health issues. Forum will create awareness, educate and empower the healthcare provider communities with new, non invasive cannabis-based therapies and treatments resulting in more favorable outcomes and wellness for patients. This meeting will assist and aid community healthcare providers and medical professionals with knowledge, research and access to cannabis-based medicines, practices and services resulting in better patient whole health.
•Identify and Learn New and Upcoming Cannabis-Based Therapies and Treatments•Understand the Provider Role in Identifying and Administering to Patients•Discuss Cancer, Chronic Pain, PTSD, Mental Health and Neurodegenerative Diseases•Recognize Medical Cannabis in Combating and Alleviating Opioid Use•Discover Best and Worst Ways Forward for Patients and Providers•Experience Present Pharmacy, Provider, Patient and Drug Delivery Models•Learn How to Integrate Medical Cannabis into Existing Provider Practices•Earn and Receive Continuing Medical Educational (CME) Credits for Physicians, Physician Assistants and Nurses and much more...
Dr. Jokubas Ziburkus PhD & Chief Innovation Officer, MariMed Inc. - early hominins started their relationship with cannabis 28 million years ago. The earliest human and cannabis interactions have likely taken place 160,000 years ago in the Tibetan plane, inhabited by Denisovans. Cannabis is one of the few plants on the planet that can stimulate human endocannabinoid system. Co-evolution of human endocannabinoid system (endocannabinoid molecules, cannabinoid receptors, and enzymes) and cannabis (phytocannabinoids, terpenes, and flavonoids) resulted in widespread modern medicinal uses of cannabis indica and industrial applications of cannabis sativa (hemp). With the latest revival of hemp crop globally and CBD oils, other cannabinoids like CBG, CBDV, CBDA are slowly entering in to the mainstream product market. Interactions between major and minor cannabinoids and terpenes allow for the holistic activation of the endocannabinoid system, often necessary to achieve effective medicinal entourage effect. Yet at the same time, both systems – sapiens and hemp are very complex and ‘one size does not fit all’. It is important for healthcare practitioners to understand the basic and clinical sciences, as well as the practical clinical applications for recommending, compounding, and dosing cannabis-derived formulations. Standardization of such complex matrices of cannabis-derived supplements into individualized products and treatments still stands as one of the most important medical challenges and treasure troves of the 21st century. Evolution of Cannabis: from Tibetan Planes to virus-induced coding of cannabinoids Human endocannabinoid system and its interaction with various components found in hemp.
The presentation will have the most up to date science and clinical evidence in a power point format. Small handouts 'Hemp CBD Guide for Healthcare Practitioners' will serve as a handout to accompany the power point presentation.
Keynote Speaker - Dustin Sulak DO, Founder Healer.com reviews the evidence supporting the use of cannabis to not only treat disease, but to prevent disease and maintain health, with practical and easy-to-implement dosing strategies. This presentation also covers non-cannabis influences on our endocannabinoid physiology and focus on chronic conditions including sleep disorders, cardiovascular disease, neurologic injury, obesity and diabetes, and more.
Keynote Speakers - Nichole Snow, President of the MA Patient Advocacy Alliance and Rep. David LeBoeuf, 17th Worcester District - Presenter of House Bill H.3875 'An Act relative to insurance coverage of medicinal cannabis' - Since the inception of the Medical Marijuana Ballot Petition passed overwhelmingly by the voters of Massachusetts, the credibility of cannabis as a true form of medicine has been challenged and even further stigmatized by nonbelievers. The Massachusetts Patient Advocacy Alliance (MPAA), the group that drafted and worked to pass this important initiative has never left the patients' side throughout the implementation of both the Medical Marijuana Law and the redrafting of the Adult Use Law in 2017 which codified the Medical Marijuana Program into statute. MPAA has never been closer to integrating cannabis into traditional healthcare. We'll share how MPAA won these essential legislative changes that gives the respect that cannabis in medicine deserves and why MPAA believes Massachusetts is the pioneer the medical community has been waiting for. In support, Nichole will introduce Mass State Rep. David LeBoeuf, who will discuss his background and interest in why he chose to draft and present Mass House Bill H.3875 'An Act relative to insurance coverage of medicinal cannabis' which garnered 9 additional co-sponsors from both the Massachusetts House and Senate leaders in the State House.
Dr. Ryan Zaklin MD, MA, PC - the Endocannabinoid System (ECS), the physiological system responsible for maintaining balance in relation to ourselves and our environment is one of the most important discoveries of this last century. Cannabinoids are the diet of the ECS. When our self-made endocannabinoids are not sufficient, we must supplement with phytocannabinoids produced by plants. Mind-body practices, such as meditation, mindfulness and yoga serve as the exercise, paving new pathways of awareness. This event will introduce the ECS to those not yet familiar, as well as give an overview on Cannabis therapeutics basics and how cannabis, along with other plants and modalities may be used to optimize the ECS, particularly as it applies to the aging population.
In depth discussions on how to;
Panel Discussion - what does the data tell us! Here we will address the risks of cannabis including dependence and addiction, and its influence on major mental illness. We’ll also dig deep and discuss the use of cannabis as an alternative to opioids and benzodiazepines, and its role, if any, in treating use disorders. Session Panelists – Jordan Tishler, MD, Kate Schultz, MSN, NP-C, add'l panelist to be announced
Adam Abodeely MD, MBA, FACS, FASCRS Founder, Owner ReserveMD - The Endocannabinoid System (ECS) plays a significant role in the health and function of our gastrointestinal system thereby making it an ideal target for cannabinoid therapy. A complex interaction exists between our gut bacteria, the human endocrine, lymphatic, and nervous system. Cannabinoid therapy is showing promise for a variety of gastrointestinal conditions aiming at managing pain and inflammation, improving the overall health of our gastrointestinal cells, affecting intestinal motility, and acting as a potential anti-cancer compound. New and emerging concepts are being explored that will continue to harness the benefits and expand the use of cannabinoids for conditions including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), cachexia, chemotherapy-induced nausea/vomiting and cancers.
Panel Discussion - our discussion will focus on the role that mind-body practices and other healthy lifestyle choices contribute to optimal functioning of the Endocannabinoid System (ECS). How to address ECS dysfunction without the use of cannabis will be examined. A few minutes of this session will be dedicated to a guided meditation provided by Dr. Zaklin. Session Panelists – Dustin Sulak DO, Ryan Zaklin, MD, MA, PC and Marissa Fratoni, RN (Moderator)
Dustin Sulak DO -10 years of clinical experience, shares his methods for creating personalized treatment plans, including relevant background information on cannabis dose-response effects, delivery method selection, strategies for the cannabis naive, experienced users, opioid-dependence, seizures, and more.
Dr. Luis Enrique Liogier-Weyback and Dr. Adam Abodeely - PTSD is a common psychiatric disorder arising from exposure to physical, emotional, and psychological trauma. This disorder affects millions of Americans every year, and it has unfortunately become a prevalent diagnosis in our nation's returning armed forces veterans. This talk will focus on the medical applications of cannabinoid therapy in the treatment of PTSD. Special focus will be paid to endocannabinoid signaling pathways in the central nervous system, neuroanatomical targets of phytocannabinoids, and a review of the literature evidence relating to cannabinoid therapy and PTSD.
Keynote Speaker - Michael Latulippe, Advisor to the Massachusetts Cannabis Control Commission and Supporting Speakers - Elizabeth Dost, Clinical Director of MPAA and Jeremiah MacKinnon, Advisory Board Member to MPAA - Protecting the medical marijuana patient supply after recreational sales begin is something that separates Massachusetts from other states that have legalized marijuana for non-medical uses. This first in the nation "Patient Supply Safety Net" was primarily the outcome of successful patient advocacy coordinated by the Massachusetts Patient Advocacy Alliance (MPAA) the group that drafted and help pass the 2012 ballot question to legalize medical use marijuana in the Commonwealth, and Michael Latulippe, the appointed registered qualifying patient advisor to the Massachusetts Cannabis Control Commission. Michael will share how he derived the term "Patient Supply Safety Net" in order to help other patient advocates push a coherent and strong message. Will further discuss and provide a few of the issues associated with the first iteration of the Cannabis Control Commission's regulations around patient supply in Massachusetts and how it can be improved upon similar to other states like Illinois commitment to developing their own version of a patient supply safety net.
Panel Discussion - Past and Present Lessons Learned and the Future of Targeted Therapy The current growth and excitement of the cannabis industry has resulted in a flurry of research focused around understanding the clinical applications of the individual compounds found within the cannabis plant. Despite this, studies have continually supported the idea that the synergy that exists between all of the compounds via the “entourage effect” is more effective than the therapeutic potential of isolated molecules such as THC or CBD alone. This discussion will focus on understanding the historical perspective and future directions surrounding cannabis strains “chemovars” and will attempt to shed some light on how relative concentrations of chemical compounds found within the plant might be harnessed to affect disease-specific outcomes. Session Panelists Dr. Jordan Tishler, Dr. Adam Abodeely
Keynote Speaker - Dr. Jordan Tishler, President of Association of Cannabis Specialists, CMO inhaleMD. Imagine if you had a serious infection and needed an antibiotic, yet no one could clearly tell you which one or how much of a dosage to take, how to administer it, or what potential side effects it may have. Such a situation anyone would be frustrated, confused and feel abandoned in the process. That lack of guidance and informed consent could be considered malpractice. Yet, in many occasions our current system for dispensing medical cannabis is close to being similar informing ill and unknowledgable patients too "figure it out”.
It seems patients can and are easily led astray by more favorable commercial sales, processes or product sets. Although like many new lines of business it takes time to nurture processes, quality control, standards etc. many see this is the case although still concerned hearing more and more cases where patient prescriptions and medications aren’t being properly provided instead many are introduced to other commercial products recommended at the point of sale. In short, the integrity of our existing process and system is flawed as this not only harms patients desperately seeking the care and relief they need, but undermines the very trust on which a medical system must abide by and built on.
The pharmacy system was developed to ensure the safety of the patients and the quality and reliability of medicines offered. Through the 20th century, legal and ethical advances increased the precision of prescriptions and ensured that proper dosage, untainted medicines, and proper information is and must be given to patients. Two essential ingredients that form the backbone of the pharmacy industry: the prescription and the prohibition of unsubstantiated medical claims.
Here we will discuss the history and development of the pharmacy industry from a regulatory standpoint, and the lessons both the federal government and our industry can take away. We will further identify and address the lessons learned from the "incubators of the states" and review what a "greatest hits" of the states' programs may look like if implemented as national policy.
Carey Clark, PhD, NP, RN - President, American Cannabis Nurses Association (ACNA) The National Council of States Boards of Nurses (NCSBN) has issued a call that all nursing's students be educated around 6 essential areas of medical cannabis care.
This talk discusses the implications of the NCSBN call, the work that that the American Cannabis Nurses Association is undertaking to help support the education of nurses around cannabis care, and the forthcoming Wolters Kluwer publication of the textbook Cannabis: A Handbook for Nurses. Learners may feel inspired to share their cannabis care knowledge with colleagues and patients and begin to formulate their own action plans for creating change and ending the lingering prohibition-era stigma.
Sherri Tutkus, RN, BSN CEO of GreenNurseGroup.com- Nursing is one of the most highly trusted professions and now that cannabis is rolling out across the country there is a greater need for more nurses to have the clinical understanding of the endocannabinoid system (ECS). We will explore how the cannabis nurse utilizes their working knowledge of the endocannabinoid system, cannabis pharmacology and current evidence for the purpose of helping patients access and effectively use cannabis as medicine. We will examine the various settings in which a cannabis nurse my provide consultation and education services, consider legal implications and career challenges faced by practicing cannabis nurses, and explore some of the entrepreneurial endeavors and nurse operated businesses in the cannabis industry.
Panel Discussion Registered Nurses sharing their knowledge and experience of being and becoming an educated cannabis nurse and further how to overcome the legal and career challenges in an ever growing cannabis healthcare economy. Session Panelists, Sherri Tutkus, RN, BSN, Jodi Chapin, RN, Marissa Fratoni, RN Nique Pichette, RN and Tonya Sanders, RN
Panel Discussion - consumers and medical professionals currently have access to a variety of products and formats. Clinical applications of medical cannabis and hemp-derived CBD are increasing, yet clinical research and disease-specific validation of cannabis products is still lacking.
Four key pillars in cannabis alternative therapy are;
Incorporating all of the above into cannabis industry practice will lead us to safe and efficacious individualized health and wellness products and medications. Session Panelists – Dr. Jokubas Ziburkus, add'l panelists to be announced
Dr. Adam Abodeely & Colleagues - the demand for cannabis products continues to grow at an astonishing pace. As the market for cannabis products (both THC and CBD) expands, so does the race to create novel ways to harness the benefits of cannabis through standard and novel techniques. Various formulations and manufacturing techniques are used in an attempt to not only enhance bio-availability but also to provide specific formulations which may act to control symptoms of specific ailments. In this presentation, Dr. Abodeely will share his experience formulating cannabis products and where the pitfalls, challenges and opportunities exist. This session will also provide guidance in what to look for to ensure quality control, transparency and product consistency. This is necessary to ensure the safety and mitigate risk for patients/consumers, manufacturers, retailers as well as the industry as a whole.
Rahim Dhalla, PharmD, RPh Hybrid Pharm Owner & Founder -1-year into federal Canadian legalization. What happens when Canada legalized cannabis? You open a cannabis specialty compounding pharmacy dedicated to helping patients utilize cannabis safely and effectively. Our talk will dive into current best practices as well as look into compounding with cannabis for specific patient populations. We will share our successes and challenges in developing Canada’s first cannabis specialty pharmacy; Hybrid Pharm
Dr. Melani Kane (Bersten), Executive Director, International Society of Cannabis Pharmacists, PharmD provides an in-depth review of the possible side effects and drug interactions with the use of Cannabinoid medicine. Audience members will review unique patient cases and develop recommendations to relieve toxicity.
Feb 18 2020
NCIA’s Northeast Cannabis Business Conference
Boston, United States
Mar 20-22 2020
The 6th Annual New England Cannabis Convention
Boston, United States
May 30-31 2020
3rd Annual Vermont Cannabis & Hemp Convention
Essex, United States
Nov 14-15 2019
Medical Cannabis Patient Therapies & Wellness Summit
Newton, United States